EurekaMag.com logo
+ Site Statistics
References:
54,215,046
Abstracts:
30,230,908
PMIDs:
28,215,208
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The effect of the aromatase inhibitor, arimidex and tamoxifen on tumour growth in a nude mouse model for postmenopausal breast cancer



The effect of the aromatase inhibitor, arimidex and tamoxifen on tumour growth in a nude mouse model for postmenopausal breast cancer



Journal of Pharmacy & Pharmacology 49(SUPPL 4): 1, Sept




(PDF emailed within 1 workday: $29.90)

Accession: 033785378

Download citation: RISBibTeXText



Related references

The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clinical Cancer Research 8(7): 2378-2388, 2002

Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Research and Treatment 85(3): 247-254, 2004

A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Research 54(19): 5092-5095, 1994

Influence of ARIMIDEX , a non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer. Breast Cancer Research & Treatment 37(SUPPL ): 72, 1996

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Research & Treatment 57(2): 183-192, Sept, 1999

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. European Journal of Cancer 32A(3): 404-412, 1996

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer 74(8): 1286-1291, 1996

Effect of aromatase inhibitor or tamoxifen therapy on steroid sulfatase activity and DHEA-DHEAS concentrations in postmenopausal women with breast cancer. Journal of Clinical Oncology 26(15_suppl): 1134-1134, 2016

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Journal of Clinical Oncology 14(7): 2000-2011, 1996

Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. Clinical Breast Cancer 5 Suppl 1: S13-S17, 2004

A randomised, double blind parallel-group trial to evaluate the effect of Arimidex on the pharmacokinetics of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Research & Treatment 46(1): 30, 1997

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of Clinical Oncology 18(22): 3748-3757, 2000

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98(9): 1802-1810, 2003

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 106(10): 2095-2103, 2006

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clinical Cancer Research 5(9): 2338-2343, 1999